EGFR and non-small cell lung carcinoma: Mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) had been identified as a significant subtype of non-small cell lung cancer (NSCLC) [2, 4], present in about 25%–50% of advanced NSCLC patients in Asia [1].